T1 Organism 1531 1539 patients
T3 Biomarker 1982 1993 Osimertinib
T4 Biomarker 2211 2221 first-line
T5 Biomarker 633 655 intravenous pemetrexed
T6 Organism 314 322 patients
T7 Biomarker 267 281 platinum-based
T8 Biomarker 939 949 first-line
T9 Biomarker 267 275 platinum
T10 Protein 1016 1032 progression-free
T11 Condition 2084 2134 T790M-positive advanced non–small-cell lung cancer
T13 Biomarker 1954 1964 pemetrexed
T14 Condition 167 176 mutations
T15 Biomarker 125 133 EGFR-TKI
T16 Biomarker 2056 2066 pemetrexed
T18 Biomarker 1678 1689 osimertinib
T19 Protein 1072 1088 progression-free
T20 Biomarker 2034 2042 platinum
T22 Organism_substance 581 597 oral osimertinib
T24 Organism 1659 1667 patients
T25 Biomarker 586 597 osimertinib
T27 Biomarker 529 538  EGFR-TKI
T28 Biomarker 519 529 first-line
T29 Biomarker 1172 1182 pemetrexed
T30 Biomarker 10 21 Osimertinib
T31 Intervention 1563 1585 central nervous system
T32 Biomarker 949 958  EGFR-TKI
T33 Biomarker 715 726 carboplatin
T34 Biomarker 1932 1940 platinum
T35 Condition 194 220 non–small-cell lung cancer
T36 Organism 2070 2078 patients
T37 Organism 419 427 patients
T40 Biomarker 2221 2230  EGFR-TKI
T41 Condition 2084 2089 T790M
T42 Biomarker 939 958 first-line EGFR-TKI
T43 Biomarker 1344 1355 osimertinib
T44 Biomarker 238 249 osimertinib
T45 Biomarker 1717 1725 platinum
T47 Biomarker 530 538 EGFR-TKI
T48 Protein 1587 1590 CNS
T49 Biomarker 519 538 first-line EGFR-TKI
T50 Intervention 2157 2171 CNS metastases
T51 Biomarker 124 133  EGFR-TKI
T52 Biomarker 853 863 pemetrexed
T53 Biomarker 1904 1915 osimertinib
T54 Biomarker 1739 1749 pemetrexed
T55 Condition 433 438 T790M
T56 Biomarker 1150 1158 platinum
T57 Organism 180 188 patients
T58 Biomarker 1128 1139 osimertinib
T59 Biomarker 2211 2230 first-line EGFR-TKI
T60 Biomarker 295 305 pemetrexed
T63 Condition 2108 2134 non–small-cell lung cancer
T64 Biomarker 1390 1398 platinum
T65 Intervention 1545 1555 metastases
T66 Intervention 770 779 cisplatin
T67 Biomarker 88 96 EGFR-TKI
T69 Protein 2157 2160 CNS
